Doctor Calls Bispecific Results “Phenomenal” in Advanced Endometrial Cancer Trial

Bradley Corr, MD, of the University of Colorado Anschutz Cancer Center, praised near‑perfect disease control seen with the bispecific antibody cadonilimab plus chemotherapy in advanced endometrial cancer.